𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Modelling Survival Data to Examine Length of Treatment Effectiveness in a Clinical Trial

✍ Scribed by Prof. Donald J. Slymen

Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
592 KB
Volume
30
Category
Article
ISSN
0323-3847

No coin nor oath required. For personal study only.

✦ Synopsis

In some clinical trials where the experimental treatment is found to beeffective in increasing survival, an important question is how long should the patient remain under treatment. Although the trial may not be designed to specifically answer this question, comparisons of the hazard curves among the treatment groups can yield some useful information. The survival data may be modelled using a flexible set of hazard functions and speoific models are then chosen for further examination. This paper illustrates the approach using data from the Beta-Blocker Heart Attack Trial. Parametric and semi-parametric models are fitted and likelihood methods are used to asseas length of treatment effectiveness.

πŸ“œ SIMILAR VOLUMES

Assessing treatment–time interaction in
Assessing treatment–time interaction in clinical trials with time to event data: a meta-analysis of hypertension trials
✍ F. Boutitie; F. Gueyffier; S. J. Pocock; J. P. Boissel πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 178 KB πŸ‘ 3 views

Exploration of the variation of treatment effect over time in randomized clinical trials with low event rates is limited by lack of power. A meta-analysis on individual patient data from such trials can partly solve the problem, but brings other computational difficulties. Using an example in hypert

A Bayesian hierarchical survival model f
A Bayesian hierarchical survival model for the institutional effects in a multi-centre cancer clinical trial
✍ Yutaka Matsuyama; Junichi Sakamoto; Yasuo Ohashi πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 159 KB πŸ‘ 2 views

In randomized clinical trials comparing treatment effects on diseases such as cancer, a multi-centre trial is usually conducted to accrue the required number of patients in a reasonable period of time. While we interpret the average treatment effect, it is necessary to examine the homogeneity of the

A Multivariate Model to Measure the Effe
A Multivariate Model to Measure the Effect of Treatments in Survival to Breast Cancer
✍ Rafael PΓ©rez-OcΓ³n; Juan Eloy Ruiz-Castro; M. Luz GΓ‘miz-PΓ©rez πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 164 KB πŸ‘ 2 views

An homogeneous Markov process in continuous time with three states (no relapse, relapse, and death) to model the influence of treatments in relapse and survival times to breast cancer is considered. Different treatments such as chemotherapy, radiotherapy, and hormonal therapy, and combinations of th

MULTI-LEVEL MODELS FOR REPEATED MEASUREM
MULTI-LEVEL MODELS FOR REPEATED MEASUREMENT DATA: APPLICATION TO QUALITY OF LIFE DATA IN CLINICAL TRIALS
✍ HEATHER J. BEACON; SIMON G. THOMPSON πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 985 KB

Quality of life data present considerable statistical challenges because of their longitudinal and multi- dimensional nature, and also because the available data are often very unbalanced through missing values. Here we exemplify the potential of multi-level models, that is, hierarchical random coe